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Neoadjuvant therapy is an under-utilized regimen for the treatment of metastatic melanoma. The use of this
approach has been increasing in other tumor types. Neoadjuvant therapy may reduce occult circulating tumor
cell burden in the face of bulky disease and afford a real time evaluation of treatment effectiveness. Neoadjuvant
approach can also provide preoperative histologic and molecular analysis of treated tissue that may guide the
postoperative treatment planning in patients with resectable metastatic melanoma lesions. The putative benefits
of better margin control and clearance of occult systemic disease would theoretically improve surgical outcome.
With the advent of effective agents against metastatic melanoma, this common approach to the treatment of
rectal cancer, metastatic colon cancer, and breast cancer should also be evaluated as a viable treatment strategy
for advanced stage melanoma.
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Malignant melanoma is a highly curable cancer when
detected early but often fatal at advanced stage. In 2010,
the prevalence of melanoma in the United States was
921,780 affected individuals. It was estimated that 76,690
additional people would be diagnosed with melanoma
and 9,480 will die of their melanoma in 2013. It has a
predilection to affect younger Americans in the prime of
their lives. In fact, it is the most common form of cancer
in young adults ages 25 to 29 years old, and the second
most common cancer in those ages 15 to 24 years old.
[1] Melanoma has a further predilection for higher
socioeconomic groups and has an estimated annual
productivity loss due to mortality of $3.5 billion [2].
Most of the melanoma cases diagnosed are in early
stages of disease and have an excellent prognosis with
86-95% 10 year survival with appropriate therapy.
Unfortunately, more advanced disease carries a poor
prognosis with American Joint Commission on Cancer
(AJCC) stage IIIB/C patients having a 24-43% 10 year
survival, and stage IV disease with a 10-15% 5 year
survival [3].* Correspondence: hsuehec@slu.edu
2Department of Surgery, Saint Louis University, 3635 Vista at Grand Blvd., St.
Louis, Missouri 63110, USA
Full list of author information is available at the end of the article
© 2013 Laks et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orCurrently, the mainstay of therapy for melanoma has
been surgical resection to render the patient clinically
free of disease for both early and select advanced stage
melanoma patients. For patients with AJCC stage I and
II melanoma, surgical therapy would entail wide excision
with or without sentinel lymph node dissection depending
on the Breslow thickness of the primary lesion and
presence of other significant prognostic variables. For
patients with AJCC stage III melanoma patients with
nodal involvement, the therapy would involve radical
lymphadenectomy. For patients with resectable AJCC
stage IV disease, metastasectomy for limited burden
disease would be the usual treatment of choice. Until
recently chemotherapeutic, biologic, and immunologic
therapies have had little success in the adjuvant setting
with only high dose interferon (HDI) having an FDA
indication in the adjuvant setting.
Over the last 4 years, the advent of targeted therapy
for BRAF mutated melanoma and immune checkpoint
inhibitors, e.g. anti-CTLA-4, anti-PD-1, and anti-PD-1 L
antibodies have sparked resurgence of excitement for the
treatment of advanced stage melanoma. With significant
portions of advanced stage melanoma patients harboring
occult systemic disease as demonstrated by subsequent
relapse after surgery and presence of CTC in peripheral
blood, neoadjuvant therapy could potentially improve. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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resectable lesions. Furthermore, response to neoadjuvant
therapy has been demonstrated to be an important
prognostic variable in several tumor types, such as
breast and colorectal cancer. The objective response to
neoadjuvant therapy would likely serve as an important
prognostic variable for stratification of care following
surgery for metastatic melanoma patients. More import-
antly, this approach would allow selection of patients
that would most likely benefit from surgery. Patients
who progressed on systemic therapy would likely have
biologically aggressive histology where early relapse can
be expected after radical resection of metastatic disease.
As promising agents are being developed and approved
for treatment in metastatic melanoma over the last
several years, [4] there have been scant reports of
neoadjuvant treatment using these new agents. To
allow an objective comparison of the upcoming neoad-
juvant regimens with these new agents, we reviewed
the literature for neoadjuvant treatment of melanoma
with the traditional regimens [Table 1] and case reports
of this approach with the recently approved agents. To
highlight the promise and potential issues of neoadjuvant
therapy for metastatic melanoma, we also report herein
our experience with post-treatment resection of residual
metastatic disease for patients with previously unre-
sectable stage IV melanoma receiving systemic therapy
as primary treatment modality.
Case reports
Our first case is a 55 years old male with a 1.3 mm
thick non-ulcerated nodular melanoma on the fore-
head. Patient underwent wide excision and sentinelTable 1 Summary of traditional neoadjuvant studies
Patients (n) Study design,end point Agent
Sasson et al. [5] 16, metastatic Retrospective, OS Various*
Jouary et al. [6] 13, metastatic Retrospective, OS DTIC
Shah et al. [7] 19, Stage III Phase II, ORR Tem
Buzaid et al. [8] 64, Stage III Phase II, ORR Cis, Vin, IL2, DTIC, I
Gibbs et al. [9] 48, Stage III Phase II, ORR Cis, Vin, IL2, DTIC, I
Koyanagi et al. [10] 63, Stage III Phase II, DFS Cis, Vin, DTIC, IL2, I
Lewis et al. [11] 92, Stage III Phase II, OS Cis, Vin, DTIC, IL2, I
Kounalakis et al. [12] 153, Stage III Retrospective, OS Cis, Vin, DTIC, IL2, I
Moschos et al. [13] 20, Stage III Phase II, ORR HDI
*Study designed to compare utility of resection vs. no resection and had various ch
camustine, cis-platin, tamoxifen, or interferon.
**Reported histological response rate.
#Only 36 of the 48 patients had clinically evaluable disease to assess response rates
##Only 50 of the 92 patients had clinically evaluable disease to assess response rate
+Only 51 of the 153 patients had clinically evaluable disease to assess response ratenode biopsy for treatment of his primary melanoma. At
year 4 of post-operative surveillance, patient recurred
with pulmonary and hepatic metastases [Figure 1A].
He underwent high-dose IL2 followed by ipilimumab
(3 mg/kg for 4 doses every 3 weeks) for progression of
disease. At 6 months post-ipilimumab treatment, mixed
responses were observed in the pulmonary lesions
with stable disease in some and regression in others.
However, the right lobe of liver lesion increased in size
from 5.4 to 7 cm [Figure 1B]. A right hepatectomy for
a 7 cm metastatic melanoma with negative margins
was performed. Postoperative surveillance revealed no
further disease in the liver and continued regression
or stabilization of the lung nodules [Figure 1C]. Follow
up PET scanning 4 months later revealed new left chest
wall and axillary recurrence and patient underwent en
bloc resection of the axillary and chest wall diseases
to negative margins. He remains progression free on
surveillance scans 4 months after resection of his chest
wall disease.
Our second patient is an 81 year old male with a
2.9 mm thick non-ulcerated right ear primary melanoma.
Patient underwent a wide excision and sentinel lymph
node with negative surgical margin and negative sentinel
lymph node. Eight months post-op, patient recurred in
the draining nodal basin and underwent a right neck
dissection with 6 of 24 positive lymph nodes and right
parotidectomy with 4 of 4 positive intra-parotid lymph
nodes. Patient subsequently recurred distantly 2 months
later with PET/CT revealing metastatic lung disease,
splenic metastases, and a focus of disease in the rectum
[Figures 2A and 3A]. Standard ipilimumab therapy was
initiated. Post treatment surveillance revealed resolutionClinical response Survival
62.5% (7PR, 3CR) OS – 68.8% DFS – 62.5%, median f/u 35 mo
60% did not progress. OS - 31.6 vs 25.3 mo
(study group vs. retrospective cohort)
16% (1PR, 2CR) NR
FN 50%**(28PR, 4 CR) Median OS 27 mo. Median DFS 13 mo
FN 38.9%# (13PR, 1CR) 79% OS, 65% PFS at 2.6 yrs.
FN NR DFS- 70%, median f/u 30.4 mo.
2 yr OS – 80.9%
FN 26%## RFS – 64% OS- 78%, median f/u 40.4 mo
FN 55% + (14 PR, 14 CR) 5 yr OS-82% (micromet disease),
and 77% (bulky disease)
55% (8PR, 3 CR) 90% PFS at 1.5 yrs.




Figure 1 Pre- and post-treatment CT images for patient 1. A. Initial metastatic disease. Small pulmonary nodules on the right anterior and
posterior lungs and a 5.4 cm lesion in the right lobe of the liver. B. Post-treatment. Stability or reduction in sizes of right lung lesions, but progression
of right lobe of liver lesion to 7 cm. C. Post right hepatectomy. Continued regression and resolution of right lung lesions, and surgical resolution of
right liver lesion.
Figure 2 Pre- and post-treatment CT images for patient 2. A. Pre-treatment CT images of metastatic lung nodules and splenic metastases.
B. Post-treatment CT images of resolving lung and splenic metastases. C. Twenty month post-treatment CT images of resolved lung and
splenic metastases.
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Figure 3 Pre- and post-treatment PET/CT images for patient 2. A. Pre-treatment PET/CT image of rectal lesion. B. Post-treatment PET/CT
image of rectal lesion. C. Post-resection PET/CT image of rectal lesion.
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uptake [Figures 2B and 3B]. Patient underwent low
anterior resection of the rectal lesion with viable tumor
on histologic analysis. He is in complete remission at
one year follow up [Figures 2C and 3C].
Neoadjuvant therapy with traditional systemic agents
For decades, single-agent dacarbazine (DTIC) has been
the standard systemic therapy for metastatic melanoma
and the control arm for most of the promising thera-
peutic intervention trials. As a single agent, objective
response rate is approximately 15% with median response
duration of 5 to 6 months and rare complete responders
[14]. Given the poor performance of single agent DTIC,
various phase I and Phase II trials of combination regi-
mens such as BOLD (bleomycin, vincristine, lomustine,
and DTIC), CVD (cisplatin, vinblastine, and DTIC),
and “Dartmouth regimen” (cisplatin, carmustine, DTIC,
and tamoxifen) have been tested and some have shown
response rates as high as 55%. However, no statistical
significant impact on overall survival can be demonstrated
with multiple randomized phase III trials of various
combination therapy versus DTIC alone [14]. Boddie
et al. reported their experience of neoadjuvant DTIC
followed by resection in four children with stage II-IIIB
melanoma [15]. All four patients were alive at follow
up of between 2–10 years. This compared favorably with
the historical 35% survival rate in childhood melanoma
at the time. Sasson et al. reported their single institution
experience with neoadjuvant therapy in 16 metastatic
melanoma patients [5]. Various regimens including single
agent DTIC or combination with camustine, cis-platin,
tamoxifen, or interferon were administered. All 16 patients
underwent resection. They observed a median survival of
35 months compared with 11.5 months in a contemporan-
eous non-resection control. Since the comparison variable
was surgical resection versus no resection, no inference
can be made about the utility of neoadjuvant approach.
Jouary et al. reported their single institution retrospective
review of single agent DTIC in the neoadjuvant setting
for melanoma pulmonary metastases [6]. In their co-
hort of 13 patients, they observed a median survival of31.6 months versus 25.3 months in the no neoadjuvant
group. They noted a survival benefit for those patients
who had stable or regressed disease during neoadjuvant
treatment compared with those who had progressive
disease. Shah et al. reported their phase II neoadjuvant
temozolomide trial in resectable stage III and IV patients
[7,16]. They observed a 16% response rate, not signi-
ficantly different from the 12-14% response rate seen
in the widely metastatic group. Of the 16%, 2 had a
complete response, 1 had a partial response, and 4 had
stable disease. Janco et al. reviewed their institutional
data of 50 vaginal/vulvar melanoma resections with a
poor median overall survival of 3.3 years and a 30.9%
5 year survival [17]. One patient received temozolomide
for vaginal cancer, but died 3 months after surgery from
progressive disease, while one vaginal and one vulvar
melanoma received carboplatin and paclitaxel with bev-
acizumab and were both disease free and alive at 2 and
5 years follow up.
Another regimen tested in the neoadjuvant setting for
melanoma was biochemotherapy. Biochemical therapy
typically consisted of vinblastine, cisplatin, DTIC, IL-2,
and interferon alpha. In a neoadjuvant study with 64
stage III melanoma patients, Buzaid et al. reported a
histologic response rate of 50% [8]. Four of the treated
patients achieved complete histologic response. Median
overall survival was 27 months and median disease-free
survival was 13 months. Gibbs et al. reported their
neoadjuvant biochemotherapy phase II study with 36
stage III patients [9]. An objective response of 38.9%
was observed with 1 complete response and 13 partial
responses. Of interest, 14 of the remaining patients had
minor response. Median overall survival and progression-
free survival were not reached. At median follow-up of
31 months, 79.2% of patients were alive and 65% were
progression-free. Koyangi et al. utilized circulating
tumor cells to monitor the effects of neoadjuvant bio-
chemotherapy in 63 patients [10]. At median follow-up
of 30.4 months, 70% of the patient cohort was clinically
disease free. Lewis et al. reported a multicenter phase II
neoadjuvant biochemotherapy trial in stage III melan-
oma patients [11]. At 42 months of follow up, a relapse
Laks et al. Experimental Hematology & Oncology 2013, 2:30 Page 5 of 8
http://www.ehoonline.org/content/2/1/30free survival of 64% and overall survival 78% were
achieved. However, only 26% clinical response rate was
observed. To ensure the safety of this aggressive approach,
Kounalakis et al. reviewed their single institution ex-
perience with 153 patients and observed no significant
increase in wound complication rates or lymphedema
with this approach [12]. They also reported a 5 year
overall survival rate of 77% in patients with clinical
adenopathy. Despite early excitement, a phase III trial
of 138 patients comparing biochemotherapy vs. high
dose interferon in the adjuvant setting was stopped early
because of futility at the interim analysis with median
follow up of 49.3 months [18].
In 1986, Creagan et al. investigated the use of interferon
alfa in disseminated malignant melanoma [19]. Interferon
alfa was shown to have a 22% overall response rate with
3 complete responses. Median progression-free survival
was 1.5 months and overall survival was 5 months.
Moschos et al. reported the results of a phase II neoad-
juvant HDI therapy in 20 patients with stage IIIB
disease [13]. A 55% clinical response rate was observed.
They also noted the correlation of response to neoad-
juvant therapy and clinical outcome with mean disease-
free survival of 32 months for the responders and
10 months for the non-responders. This observation
corroborated the findings in numerous neoadjuvant
trials in other tumor types. Despite early excitement,
no phase III trial of neoadjuvant HDI has shown
improved survival.
Neoadjuvant therapy with recently approved agents
Vemurafenib
Mutations in BRAF lead to constitutive activation of
downstream signaling of the RAS-RAF-MEK-ERK (mito-
gen-activated protein kinase) signal transduction pathway
in 40-60% of cutaneous melanoma with substitution of
glutamic acid for valine at codon 600 in 90% of the
BRAF-mutated melanoma [20,21]. In vivo, vemurafenib
suppresses ERK signaling and hence tumor cell prolif-
eration and survival in mutant BRAF melanoma, but
lacks activity in wild-type BRAF melanoma cell lines
[22-25]. In a phase III randomized trial of vemurafenib
versus DTIC in 675 patients with BRAF V600E mutated
previously untreated metastatic melanoma patients, over-
all survival was 84% for vemurafenib group and 64% for
DTIC group at 6-month analysis [26]. Despite significant
initial clinical response to mutant BRAF inhibition,
resistance soon develops and disease progresses. Resist-
ance to vemurafenib seems to be related to reactivation of
the MAP Kinase pathways [27]. Trametinib is an inhibitor
of this pathway, and has been shown to have an effect
on BRAF mutated melanoma [28]. In an open label
phase I/II trial, combination BRAF and MEK inhibition
with dabrafenib and trametinib (respectively) improvedprogression free survival from 5.8 months with dabrafenib
monotherapy to 9.4 months with combination therapy in
metastatic melanoma patients with BRAF V600 mutation
[29]. Response rate with combination therapy was 76%
in comparison to 54% with monotherapy (p = 0.03).
An increased duration of response of 10.5 months vs.
5.6 months was also observed.
With the impressive responses observed in vemurafenib
trials, several investigators have attempted to use BRAF
inhibition in the neoadjuvant setting. Fadaki et al. reported
a case of a 58 year old with bulky stage IIIC unresectable
melanoma from the left axilla and neck that they treated
with 4 months of vemurafenib therapy with an impressive
clinical and radiographic response to allow resection of
the disease [30]. Following neck and axillary dissections,
only 1 microscopic foci of viable tumor in 40 lymph
nodes was noted. Tumor necrosis changes were observed
in the other nodes. The patient also received adjuvant
vemurafenib, and was disease free at 6 month follow up
at the publication date. Koers et al. reported a 47 year old
man who presented with bulky axillary and supraclavicular
disease matted to the surrounding skin and chest wall
from unknown primary site [31]. Patient was treated
with vemurafenib with resulting radiological and clinical
response followed by radical resection. Histological
analysis of surgical specimen revealed only minimal
residual viable tumor with negative margins. Patient
was disease free at time of the report. Kolar et al.
reported the use of neoadjuvant vemurafenib in a
patient with a large symptomatic brain metastasis that
was initially not amenable to resection [32]. Following
clinical response with vemurafenib treatment, resection of
brain metastasis was performed with negative margins
and no viable tumor left in the specimen. Patient
underwent postoperative radiation and had no evidence
of local recurrence at 12 month follow up.
Ipilimumab
Another novel agent recently approved for the treatment
of metastatic melanoma is ipilimumab, a fully human
monoclonal antibody that blocks cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4), an immune checkpoint
molecule. CTLA-4 plays a key role in the suppression
of T cell activation [33-35]. CTLA-4 blockade has been
shown to decrease the regulatory affect and increase
downstream mediators of the immune response such as
IL2, IL10, and interferon [36,37]. Weber et al. reported their
phase II study using ipilimumab in 115 treatment-naïve
melanoma patients with unresectable stage III or IV disease
[38]. Patient were randomized to ipilimumab at 10 mg/kg
every 3 weeks for 4 doses with or without budesonide. They
observed a best overall response rate (BORR) of 12% in
budesonide group and 15.8% in placebo group. The disease
control rate (DCR) was 31.0% and 35.1%, respectively.
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patient with unresectable stage III or stage IV disease
who had progressed on other therapies [39]. Patients
were randomized in a 3:1:1 fashion to ipilimumab with or
without gp100 vaccine and vaccine alone. The 3 mg/kg
dosage of ipilimumab was used. They observed an
improvement of overall survival with 6.4 months in the
vaccine alone group and 10 months in the ipilimumab
groups. An overall response rate to ipilimumab of
29.5% was observed with 60% of responses lasting
over 2 years. Further inhibition of other checkpoint
molecules appeared to increase clinical response. Wolchok
et al. reported a phase II study with combination of
ipilimumab and nivolumab (an antibody against the
programmed death 1 [PD-1] receptor) given in a concur-
rent or sequential fashion [40]. Patients in the concurrent
regimen had a 40% clinical response rate compared
with 20% in the sequential regimen group. At the
maximum doses with acceptable side effects, 53% clinical
responses were observed. Hamid et al. reported the
results of another anti-PD-1 antibody, lambrolizumab,
in 135 previously treated metastatic melanoma patients
including those patients who progressed on ipilimumab
[41]. Objective response rate of 38% was observed.
Responses were durable with median follow up of
11 months for patients who had responses.
Although no neoadjuvant experience with Ipilimumab
has been reported, Gyorki et al. reported their immuno-
logic observation in 23 patients undergoing surgery
within 30 days or receiving the treatment during the
induction or maintenance phase of Ipilimumab therapy
[42]. Only grade 1 or 2 wound complications were observed
in 22% of the patient cohort. There were no grade 3–5
complications. In 10 patients with available matched
tumor specimen and peripheral blood samples, signifi-
cantly higher percentage of CD4 + FOXP3+ T-regulatory
cells and lower ratio of CD8+/CD4 + FOXP3+ in the
tumor compared with blood were reported. Safety of
preoperative ipilimumab therapy has also been evaluated
in 12 surgical patients with urothelial carcinoma of the
bladder [43]. Only grade I/II toxicities were observed.
The University of Pittsburgh is enrolling patients in a
neoadjuvant study of ipilimumab in the setting of
resectable stage IIIB/C patients, and have released
some initial data in regards to immune monitoring
and clinical response, but the final analysis of this trial
are eagerly awaited [44].
Other reported uses of neoadjuvant therapy in melanoma
Radiotherapy has been shown to be effective in the
adjuvant setting in advanced stage III melanoma by
Intergroup Randomized Trial (TROG 02.01/ANZMTG
01.02) [45]. Foote et al. reported their experience with
neoadjuvant radiation in 12 patients with histologicallyproven stage III melanoma [46]. Following radiotherapy,
restaging work up revealed progression of disease in 2
patients and resection was not attempted. Ten patients
underwent lymphadenectomy with local disease control
rate of 92% at 1 year and 1 year disease free survival of
54%. Surgical complications were minor. Based on these
encouraging results, the investigators are conducting a
multicenter phase II study.
Mozzillo et al. reported the neoadjuvant use of elec-
trochemotherapy in a patient with isolated large subcu-
taneous metastasis to the cheek [47]. Based on clinical
evaluation, patient would have required a complex and
disfiguring resection for clearance of disease. Following
a regimen of intravenous bleomycin and local tumor
ablation with electroporation (Cliniporator) for 2 cycles
they were able to obtain significant tumor shrinkage.
Patient underwent an excision with simple local recon-
struction three months after the second treatment with
no viable tumor on histologic analysis of the surgical
specimen. Patient remained disease free at 1 year follow up.
Discussion
Melanoma is an increasingly prevalent disease that has
a predilection for the young and productive members
of our society with an immeasurable social, economic,
and emotional cost. The disappointing historical results
of melanoma systemic therapy are rapidly replaced with
promising effective therapeutics targeting multiple path-
ways in tumor growth and immune suppression. While
the initial studies of novel agents were tested as single
agent in the metastatic settings as proof of principle, the
most effective way to treat metastatic melanoma may
encompass targeting tumor growth, reversing tumor
immune suppression, and cytoreduction of clinical tumor
bulk. Neoadjuvant approach is historically under-utilized
in the treatment of metastatic melanoma in comparison
to other tumor types mainly due to the ineffectiveness
of systemic therapy. The promising results of biochem-
otherapy neoadjuvant trials and the emergence of active
agents in melanoma suggested that this approach
would shed light on the rational selection of optimal
treatment for metastatic melanoma patients.
We have presented two cases of post-ipilimumab
resection of residual disease in patients with metastatic
melanoma. Others have reported their case reports
with post-vemurafenib resection of residual disease.
These case series were not considered “neoadjuvant” in
the typical sense, i.e. surgery was only contemplated
after treatment rendered the patients surgical candidates.
The case reports cited herein demonstrates the potential
and most apparent benefit of neoadjuvant therapy for
metastatic melanoma where tumor bulk shrinkage was
achieved with systemic therapy followed by margin-
negative resection. It is yet to be demonstrated, as with
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improve survival as compared with upfront radical
surgery followed by adjuvant therapy. The two cases
reported herein illustrated the other potential benefit
and challenge facing the design of neoadjuvant therapy
for melanoma. Since melanoma readily metastasizes to
multiple organ sites, neoadjunvant treatment may
allow the selection of optimal surgical patient cohort
where no new lesions appear during treatment. As
demonstrated in our first patient, although growth of
liver lesion was observed during treatment, there was
regression and stabilization of pulmonary lesions with
no new lesions developed during treatment. With the
increasing evidence showing the efficacy of immune
checkpoint therapy for melanoma and the prolonged
response time reported, the determination of optimal
timing of surgery would be instrumental in the design
of neoadjuvant therapy with this class of agents.
With the recent breakthrough in melanoma treatment
and availability of multiple effective agents, the choice of
agent or agents and the timing of treatment sequence
would be crucial for successful outcome in designing a
neoadjuvant treatment for metastatic melanoma. While
targeted therapy such as BRAF and MEK inhibitors
can effect early shrinkage of tumor bulk increasing the
resectability of target lesions, the durability of response
with this class of treatment has not been uniformly
reported and may not have significant impact on overall
survival. Conversely, immune checkpoint therapy can
confer a durable disease control but tumor shrinkage is
protracted several months and responses in multiple
lesions may not be uniform, i.e. progression in some
lesions and regression in others. Identification of optimal
patient population and optimal combination for neoad-
juvant approach and the concurrent biomarker studies
would further advance our treatment of metastatic
melanoma patients. With limited data available in the
neoadjuvant treatment of melanoma with these new
agents, we are eagerly awaiting the results of the University
of Pittsburgh trial of ipilimumab in the stage IV setting.
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